Intravenous immunoglobulins control scleromyxoedema

Intravenous immunoglobulins control scleromyxoedema.

BACKGROUND Scleromyxoedema is a variant of papular mucinosis affecting the skin and internal organs. The different therapeutic approaches proposed for scleromyxoedema are still unsatisfactory. Intravenous immunoglobulin (IVIg) has been successfully employed in the treatment of connective tissue diseases and vasculitides. PATIENTS The successful treatment of three cases of scleromyxoedema with...

Arndt-Gottron scleromyxoedema: successful therapy with intravenous immunoglobulins.

SIR, Arndt–Gottron scleromyxoedema is a rare fibromucinous disorder regarded as a variant of the lichen myxoedematosus. The diagnostic criteria are a generalized papular and sclerodermoid eruption, a microscopic triad of mucin deposition, fibroblast proliferation and fibrosis, a monoclonal gammopathy (mostly IgG-k paraproteinaemia) and the absence of a thyroid disorder. This disease initially p...

Long-term efficacy of high doses of intravenous immunoglobulins in generalized scleromyxoedema: Case report

Scleromyxoedema is a rare disease with a progressive and disabling course involving dermal deposition of mucin and fibroblast proliferation; it is characterized clinically by a diffuse papular eruption, skin thickening, oedema and decreased skin flexibility, especially of the face and hands. Current therapy options are based on evidence from a limited number of case reports. The clinical manife...

Intravenous Immunoglobulins in the Therapy Of

Intravenous immunoglobulin (IVIG) is used for the treatment of numerous immunodeficiency, immune-mediated, and inflammatory disorders in humans. More recently, it has been described for the therapy of immune-mediated hematologic disease in dogs. While the potential benefits of IVIG are tantalizing, and initial reports in dogs are encouraging, there is a marked paucity of controlled studies in t...

Autoimmune neuropathies and treatment with intravenous immunoglobulins